OVERVIEW

Exploring the Potential of Extended Half-Life Products in Hemophilia A: A Fresh Take on Standard Prophylaxis is organized by American Academy of CME, Inc.

Released On: September 16, 2019
Expires On: September 16, 2020

Accreditation:
• 1.50 / AMA PRA Category 1 Credits™

Program Overview:
Many PWHA experience elevated bleed rates, suggesting that there may be additional steps clinicians need to take to minimize bleeding in this patient population. This educational video roundtable is designed to improve clinicians’ knowledge regarding prophylactic FVIII replacement therapy in preventing bleeding and bleed-related complications. This education will also help clinicians better recognize factors that can decrease adherence to FVIII replacement strategies. It will also help them explore the potential role in new EHL products in improving adherence and overall outcomes on PWHA in order that they will be better able to utilize and tailor EHL products for appropriate patients.

Learning Objectives:
After completing this activity, the participant should be better able to:
• Describe the current use/underuse of prophylactic factor VIII (FVIII) replacement therapy in preventing bleeding and bleed-related • complications in people with hemophilia A (PWHA)
• Identify treatment factors that can decrease adherence to FVIII replacement strategies
• Compare the pharmacokinetic profiles of new extended half-life (EHL) products to traditional replacement products
• Develop a strategy for how to incorporate new EHL products as part of an individualized approach to hemophilia A prophylaxis

Additional details will be posted as soon as information is available.